Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis.

Medicine (Baltimore) · 2015 · PMC4602497 · PMID 25789951

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although not differing significantly, the combination of COT plus UDCA showed a trend in reducing the risk of MOLT when compared with OBS (HR 2.05, 95% CI 0.50–8.93), monotherapy with UDCA (HR 2.63, 95% CI 0.72–10.75), COC plus UDCA (HR 2.55, 95% CI 0.44–15.03), MTX plus UDCA (HR 3.58, 95% CI 0.61–21.96), or BEF plus UDCA (HR 3.48, 95% CI 0.21–56.93).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.